Syndax Pharmaceuticals (SNDX) Restructuring Costs (2024 - 2025)
Syndax Pharmaceuticals' (SNDX) quarterly Restructuring Costs came in at $4.8 million in Q4 2025, down 8.45% year-on-year from $5.2 million in Q4 2024, and down 47.3% quarter-over-quarter from $9.1 million in Q3 2025.
Syndax Pharmaceuticals (SNDX) Restructuring Costs (2024 - 2025) Analysis & Trends
Syndax Pharmaceuticals' Restructuring Costs history runs 2 years deep, the most recent figure standing at $4.8 million for Q4 2025.
- On a quarterly basis, Restructuring Costs fell 8.45% year-over-year to $4.8 million in Q4 2025; TTM through Mar 2026 was $18.9 million, a 10.49% decrease from a year earlier, with the FY2025 full-year figure at $23.3 million, up 34.33% from the prior year.
- Restructuring Costs retreated to $4.8 million in Q4 2025 per SNDX's latest filing, from $9.1 million in the prior quarter.
- Across five years, Restructuring Costs topped out at $11.8 million in Q2 2024 and bottomed at $247000.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Syndax Pharmaceuticals | 1.87 Bn | 1.52 Bn | 53.02 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 4.80 Mn |
| Sep 30, 2025 | 9.11 Mn |
| Jun 30, 2025 | 4.99 Mn |
| Mar 31, 2025 | 247,000.00 |
| Dec 31, 2024 | 5.24 Mn |
| Sep 30, 2024 | 3.85 Mn |
| Jun 30, 2024 | 11.77 Mn |